Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?

Dirk De Ruysscher*, Jordi Remon, Lizza E L Hendriks

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)149-151
Number of pages3
JournalEuropean Journal of Cancer
Early online date17 Mar 2022
Publication statusPublished - May 2022

Cite this